Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Considerations

– Intermediate Dry AMD Treatment Highlighted as Significant Unmet Need – Only Mitochondrial Stabilizing Candidates, Including Allegro’s Risuteganib, Have Shown Best Corrected Visual Acuity (BCVA) Gains in this Patient Population SAN JUAN CAPISTRANO, Calif., Feb. 10, 2023 /PRNewswire/ –…